ES2523837T3 - Agentes de unión específica al factor de crecimiento de hepatocitos - Google Patents

Agentes de unión específica al factor de crecimiento de hepatocitos Download PDF

Info

Publication number
ES2523837T3
ES2523837T3 ES04776560.7T ES04776560T ES2523837T3 ES 2523837 T3 ES2523837 T3 ES 2523837T3 ES 04776560 T ES04776560 T ES 04776560T ES 2523837 T3 ES2523837 T3 ES 2523837T3
Authority
ES
Spain
Prior art keywords
growth factor
specific binding
binding agents
hepatocyte growth
image
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES04776560.7T
Other languages
English (en)
Inventor
Teresa L. Burgess
Angela Coxon
Larry L. Green
Ke Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Amgen Fremont Inc
Original Assignee
Amgen Inc
Amgen Fremont Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc, Amgen Fremont Inc filed Critical Amgen Inc
Application granted granted Critical
Publication of ES2523837T3 publication Critical patent/ES2523837T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Cosmetics (AREA)

Abstract

Anticuerpo aislado que puede unirse a al menos un polipeptido seleccionado de * SEQ ID NO: 164; * SEQ ID NO: 165; * SEQ ID NO: 123; * aminoacidos 495-556 de HGF humano; * aminoacidos 507-585 de HGF humano; y * aminoacidos 506-728 de HGF humano, en el que el anticuerpo puede neutralizar la union de HGF a c-Met.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
imagen14
imagen15
imagen16
imagen17
imagen18
imagen19
imagen20
imagen21
imagen22
imagen23
imagen24
imagen25
imagen26
imagen27
imagen28
imagen29
imagen30
imagen31
imagen32
imagen33
imagen34
imagen35
imagen36
imagen37
imagen38
imagen39
imagen40
imagen41
imagen42
imagen43
imagen44
imagen45
imagen46
imagen47
imagen48
imagen49
imagen50
imagen51
imagen52
imagen53

Claims (1)

  1. imagen1
    imagen2
    imagen3
    imagen4
    imagen5
    imagen6
    imagen7
    imagen8
    imagen9
    imagen10
    imagen11
    imagen12
    imagen13
    imagen14
    imagen15
    imagen16
    imagen17
    imagen18
    imagen19
    imagen20
    imagen21
    imagen22
    imagen23
    imagen24
    imagen25
    imagen26
    imagen27
    imagen28
    imagen29
    imagen30
    imagen31
    imagen32
    imagen33
    imagen34
    imagen35
    imagen36
    imagen37
    imagen38
    imagen39
    imagen40
    imagen41
    imagen42
    imagen43
    imagen44
    imagen45
    imagen46
    imagen47
ES04776560.7T 2003-07-18 2004-07-16 Agentes de unión específica al factor de crecimiento de hepatocitos Expired - Lifetime ES2523837T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US48868103P 2003-07-18 2003-07-18
US488681P 2003-07-18
PCT/US2004/018936 WO2005017107A2 (en) 2003-07-18 2004-07-16 Specific binding agents to hepatocyte growth factor

Publications (1)

Publication Number Publication Date
ES2523837T3 true ES2523837T3 (es) 2014-12-01

Family

ID=34193077

Family Applications (1)

Application Number Title Priority Date Filing Date
ES04776560.7T Expired - Lifetime ES2523837T3 (es) 2003-07-18 2004-07-16 Agentes de unión específica al factor de crecimiento de hepatocitos

Country Status (26)

Country Link
US (2) US8609090B2 (es)
EP (2) EP2341067A1 (es)
JP (4) JP5105874B2 (es)
KR (2) KR101254371B1 (es)
CN (3) CN103755807A (es)
AR (3) AR042955A1 (es)
AU (1) AU2004265595B2 (es)
BR (1) BRPI0412885A (es)
CA (1) CA2532027C (es)
DK (1) DK1648998T3 (es)
EA (1) EA015363B1 (es)
ES (1) ES2523837T3 (es)
HK (1) HK1199266A1 (es)
IL (1) IL172906A0 (es)
ME (1) MEP31408A (es)
MX (1) MXPA06000508A (es)
NO (1) NO20060600L (es)
NZ (1) NZ544797A (es)
PL (1) PL1648998T3 (es)
PT (1) PT1648998E (es)
RS (1) RS53476B (es)
SG (1) SG131943A1 (es)
SI (1) SI1648998T1 (es)
TW (3) TW201319088A (es)
WO (1) WO2005017107A2 (es)
ZA (2) ZA200601353B (es)

Families Citing this family (197)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040208876A1 (en) 2003-04-18 2004-10-21 Kim Kyung Jin Monoclonal antibodies to hepatocyte growth factor
US7220410B2 (en) 2003-04-18 2007-05-22 Galaxy Biotech, Llc Monoclonal antibodies to hepatocyte growth factor
NZ544797A (en) * 2003-07-18 2011-04-29 Amgen Fremont Inc Specific antibodies that bind HGF and neutralise binding of HGF to met
HN2004000285A (es) 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
US7046714B2 (en) * 2003-09-10 2006-05-16 Intel Corporation Method and apparatus for Raman ring resonator based laser/wavelength converter
NZ552476A (en) * 2004-06-10 2009-09-25 Viventia Biotech Inc Tumor specific antibody
ES2931949T3 (es) * 2005-03-29 2023-01-05 Univ Pennsylvania Minoxidilo para generar nuevos folículos pilosos y tratar la calvicie
ZA200710599B (en) 2005-04-15 2009-08-26 Genentech Inc HGF Beta chain variants
KR20080026562A (ko) * 2005-06-02 2008-03-25 갤럭시 바이오테크, 엘엘씨 항체를 이용한 뇌종양 치료 방법
JP2009504685A (ja) * 2005-08-15 2009-02-05 アラーナ・テラピューティクス・リミテッド 新世界霊長類フレームワーク領域を用いる設計された抗体
WO2007070948A1 (en) * 2005-12-20 2007-06-28 Arana Therapeutics Limited Anti-inflammatory dab
CN103232540A (zh) * 2006-02-01 2013-08-07 赛法隆澳大利亚控股有限公司 结构域抗体构建体
AR059922A1 (es) 2006-04-01 2008-05-07 Galaxy Biotech Llc Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos
JP4560582B2 (ja) * 2006-06-02 2010-10-13 アベオ ファーマシューティカルズ， インコーポレイテッド 肝細胞成長因子（ｈｇｆ）結合蛋白質
SG158112A1 (en) 2006-06-02 2010-01-29 Aveo Pharmaceuticals Inc Hepatocyte growth factor (hgf) binding proteins
CL2007002225A1 (es) * 2006-08-03 2008-04-18 Astrazeneca Ab Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un
CL2007002567A1 (es) 2006-09-08 2008-02-01 Amgen Inc Proteinas aisladas de enlace a activina a humana.
JP2010504974A (ja) 2006-09-28 2010-02-18 フォリカ，インコーポレーテッド 新しい毛嚢を生成させ毛髪を成長させる方法、キット、及び組成物
US20080139790A1 (en) * 2006-12-08 2008-06-12 Jennings Philip A Chimeric antibodies
US7951368B2 (en) * 2007-06-25 2011-05-31 Amgen Inc. Compositions of specific binding agents to hepatocyte growth factor
MX2010002249A (es) * 2007-08-31 2010-03-17 Amgen Inc Formulacion de proteina de estado solido.
US7982016B2 (en) 2007-09-10 2011-07-19 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
MX2010002683A (es) 2007-09-14 2010-03-26 Amgen Inc Poblaciones de anticuerpos homogeneos.
AU2008304111B2 (en) 2007-09-27 2014-04-24 Amgen Inc. Pharmaceutical formulations
EP3381445B1 (en) 2007-11-15 2023-10-25 Amgen Inc. Aqueous formulation of antibody stablised by antioxidants for parenteral administration
TW201002346A (en) * 2008-04-11 2010-01-16 Galaxy Biotech Llc Combination of HGF inhibitor and EGF inhibitor to treat cancer
CL2009000844A1 (es) * 2008-04-11 2009-06-12 Galaxy Biotech Llc Metodo para tratar cancer en un paciente que comprende la administracion de un primer agente que es inhibidor de factor de crecimiento de hepatocito (hgf) en combinacion con un segundo agente que es agonista de pten.
JP5646457B2 (ja) * 2008-04-29 2014-12-24 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリン及びその使用
BRPI0912035A2 (pt) 2008-05-29 2017-05-23 Galaxy Biotech Llc anticorpo monoclonal, composição farmacêutica, uso de uma composição farmacêutica, mab de camundongo na forma quimérica ou humanizada, e, anticorpo humanizado
PE20100054A1 (es) 2008-06-03 2010-03-03 Abbott Lab Inmunoglobulina con dominio variable dual
EP3002299A1 (en) 2008-06-03 2016-04-06 AbbVie Inc. Dual variable domain immunoglobulins and uses thereof
MX2010014574A (es) 2008-07-08 2011-04-27 Abbott Lab Inmunoglobulinas de dominio variable dual para prostaglandina e2 y usos de las mismas.
AU2013202410B2 (en) * 2008-07-16 2014-10-09 Institute For Research In Biomedicine Human cytomegalovirus neautralizing antibodies and use thereof
UA112050C2 (uk) * 2008-08-04 2016-07-25 БАЄР ХЕЛСКЕР ЛЛСі Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi)
US20110229469A1 (en) * 2008-10-01 2011-09-22 Ludwig Institute For Cancer Research Methods for the treatment of cancer
PL3290052T3 (pl) 2008-11-07 2020-06-29 Galaxy Biotech, Llc Przeciwciała monoklonalne swoiste dla receptora 2 czynnika wzrostu fibroblastów
AU2009314111A1 (en) * 2008-11-12 2010-05-20 Merck Sharp & Dohme Corp. BetaGI-IgG intron for enhanced anti-IGF1 R expression
US20120052064A1 (en) 2009-04-17 2012-03-01 Yuuki Ito Anti-hgf antibody combinational cancer therapies
MX2011011670A (es) * 2009-05-01 2011-11-18 Abbott Lab Inmunoglobulinas de dominio variable dual y usos de las mismas.
TW201109438A (en) * 2009-07-29 2011-03-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
AR078254A1 (es) 2009-09-01 2011-10-26 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
CN105080183B (zh) * 2009-09-16 2017-05-10 米普萨卢斯公司 多特异性受体的改进的纯化
MX2012004415A (es) * 2009-10-15 2012-05-08 Abbott Lab Inmunoglobulinas de dominio variable doble y usos de las mismas.
MX344382B (es) 2009-10-23 2016-12-14 Amgen Inc * Adaptador de vial y sistema.
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
RS59830B1 (sr) 2010-03-01 2020-02-28 Bayer Healthcare Llc Optimizovana monoklonska antitela protiv inhibitora puta faktora tkiva (tfpi)
ES2545411T5 (es) 2010-06-07 2024-04-05 Amgen Inc Dispositivo de administración de fármaco
AU2011267869A1 (en) * 2010-06-14 2013-01-10 Vaccinex, Inc. Anti-VEGF antibodies and uses thereof
JP2013532627A (ja) 2010-07-01 2013-08-19 武田薬品工業株式会社 ｃＭＥＴ阻害剤とＨＧＦおよび／またはｃＭＥＴに対する抗体との組み合わせ
US8735546B2 (en) 2010-08-03 2014-05-27 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
PH12013500337A1 (en) 2010-08-26 2017-08-23 Abbvie Inc Dual variable domain immunoglobulins and uses thereof
CN103391773A (zh) 2010-09-27 2013-11-13 埃克塞里艾克西斯公司 用于治疗去势抵抗性前列腺癌和成骨性骨转移的met和vegf的双重抑制剂
ES3005233T3 (en) 2010-10-01 2025-03-14 Modernatx Inc Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
SG190362A1 (en) 2010-11-24 2013-06-28 Glaxo Group Ltd Multispecific antigen binding proteins targeting hgf
WO2012078649A1 (en) 2010-12-06 2012-06-14 Follica, Inc. Methods for treating baldness and promoting hair growth
SI2500036T1 (sl) * 2011-03-18 2014-09-30 Metheresis Translational Research Sa Met inhibitorji za izboljĺ anje uäśinkovitosti obsevanja
CA2831100C (en) 2011-03-31 2020-02-18 Mark Dominis Holt Vial adapter and system
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
CA3021845C (en) 2011-04-20 2022-03-29 Amgen Inc. Autoinjector apparatus
WO2013006486A2 (en) 2011-07-01 2013-01-10 Ngm Biopharmaceuticals, Inc. Compositions, uses and methods for treatment of metabolic disorders and diseases
US20140234328A1 (en) 2011-09-09 2014-08-21 Amgen Inc. Use of c-met protein for predicting the efficacy of anti-hepatocyte growth factor ("hgf") antibodies in esophageal and gastric cancer patients
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2763701B1 (en) 2011-10-03 2018-12-19 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
LT3045187T (lt) 2011-10-14 2019-07-10 Amgen Inc. Injekcijų įrenginys ir surinkimo būdas
JP2015501844A (ja) 2011-12-16 2015-01-19 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 修飾ヌクレオシド、ヌクレオチドおよび核酸組成物
US9120870B2 (en) 2011-12-30 2015-09-01 Abbvie Inc. Dual specific binding proteins directed against IL-13 and IL-17
WO2013151663A1 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of membrane proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
EP2847219A1 (en) 2012-05-07 2015-03-18 Amgen Inc. Anti-erythropoietin antibodies
WO2014004549A2 (en) 2012-06-27 2014-01-03 Amgen Inc. Anti-mesothelin binding proteins
WO2014058389A1 (en) 2012-10-12 2014-04-17 Agency For Science, Technology And Research Optimised heavy chain and light chain signal peptides for the production of recombinant antibody therapeutics
AU2013337775B2 (en) 2012-11-01 2017-03-30 Abbvie Inc. Anti-VEGF/DLL4 dual variable domain immunoglobulins and uses thereof
ES2831374T3 (es) * 2012-11-21 2021-06-08 Janssen Biotech Inc Anticuerpos de EGFR/c-Met biespecíficos
US9695228B2 (en) * 2012-11-21 2017-07-04 Janssen Biotech, Inc. EGFR and c-Met fibronectin type III domain binding molecules
US20170275367A1 (en) 2012-11-21 2017-09-28 Janssen Biotech, Inc. Bispecific EGFR/C-Met Antibodies
SI3081249T1 (sl) 2012-11-21 2021-03-31 Amgen Inc. Naprava za dajanje zdravila
ES2921623T3 (es) 2012-11-26 2022-08-30 Modernatx Inc ARN modificado terminalmente
US9290557B2 (en) 2012-11-28 2016-03-22 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides
WO2014085365A2 (en) 2012-11-28 2014-06-05 Ngm Biopharmaceuticals, Inc. Compositions and methods for treatment of metabolic disorders and diseases
US9273107B2 (en) 2012-12-27 2016-03-01 Ngm Biopharmaceuticals, Inc. Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
IL292303A (en) 2012-12-27 2022-06-01 Ngm Biopharmaceuticals Inc Methods for modulating bile acid homeostatsis and treatment of bile acid disorders and disease
WO2014108854A1 (en) 2013-01-09 2014-07-17 Fusimab Ltd. Monospecific anti-hgf and anti-ang2 antibodies and bispecific anti-hgf/anti-ang2 antibodies
CA2904713A1 (en) 2013-03-11 2014-10-09 Amgen Inc. Protein formulations comprising darbepoetin
US9481725B2 (en) 2013-03-14 2016-11-01 Alderbio Holdings, Llc Antibodies to HGF and compositions containing
KR20150140685A (ko) * 2013-03-14 2015-12-16 앨더 바이오파마슈티컬즈, 인코포레이티드 Hgf에 대한 항체 및 이를 포함하는 조성물
EP2968775B1 (en) 2013-03-15 2019-12-18 Amgen Inc. Drug cassette, autoinjector, and autoinjector system
TWI580451B (zh) 2013-03-15 2017-05-01 安美基公司 用於注射器之匣盒及使用具有自動注射器及匣盒之自動注射器設備之方法
CN105142695B (zh) 2013-03-15 2020-06-02 安进公司 身体轮廓可调适的自动注射器装置
EP2970459A2 (en) 2013-03-15 2016-01-20 AbbVie Inc. Dual specific binding proteins directed against il-1beta and il-17
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
SG11201507878SA (en) 2013-03-22 2015-10-29 Amgen Inc Injector and method of assembly
KR102060540B1 (ko) 2013-04-03 2019-12-31 삼성전자주식회사 항 c-Met 항체 및 항 Ang2 항체를 포함하는 병용 투여용 약학 조성물
WO2015031578A1 (en) * 2013-08-28 2015-03-05 Abbvie Inc. Hgf assay
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
KR20160067219A (ko) 2013-10-03 2016-06-13 모더나 세라퓨틱스, 인코포레이티드 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
EP3060281B1 (en) 2013-10-24 2019-01-30 Amgen Inc. Drug delivery system with temperature-sensitive control
EP3421066B1 (en) 2013-10-24 2021-03-03 Amgen Inc. Injector and method of assembly
WO2015119906A1 (en) 2014-02-05 2015-08-13 Amgen Inc. Drug delivery system with electromagnetic field generator
MX2016012285A (es) 2014-03-24 2017-01-23 Genentech Inc Tratamiento de cáncer con antagonista de c-met y correlación de estos con la expresión de hgf.
JP6640113B2 (ja) 2014-05-07 2020-02-05 アムジエン・インコーポレーテツド 衝撃低減要素を有する自動注入器
WO2015183890A2 (en) 2014-05-28 2015-12-03 Ngm Biopharmaceuticals, Inc. Methods and compositions for the treatment of metabolic disorders and diseases
CN112237662B (zh) 2014-06-03 2022-10-21 安姆根有限公司 药物递送系统和使用方法
WO2015195509A2 (en) 2014-06-16 2015-12-23 Ngm Biopharmaceuticals, Inc. Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
WO2016061220A2 (en) 2014-10-14 2016-04-21 Amgen Inc. Drug injection device with visual and audio indicators
WO2016065106A1 (en) 2014-10-23 2016-04-28 Ngm Biopharmaceuticals, Inc. Pharmaceutical compositions comprising peptide variants and methods of use thereof
WO2016073855A1 (en) 2014-11-07 2016-05-12 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
US11357916B2 (en) 2014-12-19 2022-06-14 Amgen Inc. Drug delivery device with live button or user interface field
EP3848072A1 (en) 2014-12-19 2021-07-14 Amgen Inc. Drug delivery device with proximity sensor
CA2976935C (en) 2015-02-17 2020-03-10 Amgen Inc. Drug delivery device with vacuum assisted securement and/or feedback
WO2016138434A1 (en) 2015-02-27 2016-09-01 Amgen Inc. Drug delivery device having a needle guard mechanism with a tunable threshold of resistance to needle guard movement
PL3298021T3 (pl) 2015-05-18 2019-11-29 Tolero Pharmaceuticals Inc Proleki alvocidibu o zwiększonej biodostępności
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
WO2017024073A1 (en) 2015-08-03 2017-02-09 Tolero Pharmaceuticals, Inc. Combination therapies for treatment of cancer
WO2017039786A1 (en) 2015-09-02 2017-03-09 Amgen Inc. Syringe assembly adapter for a syringe
JP7628764B2 (ja) 2015-09-29 2025-02-12 アムジエン・インコーポレーテツド Ａｓｇｒ阻害剤
CN106589128B (zh) * 2015-10-20 2020-03-03 天津医科大学 肝癌标志物单克隆抗体的制备及其应用
US10941204B2 (en) 2015-10-30 2021-03-09 Galaxy Biotech, Llc Highly potent antibodies binding to death receptor 4
CN106674350B (zh) * 2015-11-09 2020-03-03 天津医科大学 肝癌标志物单链抗体的制备及其应用
AU2016353988B2 (en) 2015-11-09 2019-09-26 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders
ES2755717T3 (es) 2015-12-09 2020-04-23 Amgen Inc Autoinyector con tapa de señalización
US11154661B2 (en) 2016-01-06 2021-10-26 Amgen Inc. Auto-injector with signaling electronics
US11200298B2 (en) 2016-03-15 2021-12-14 Amgen Inc. Reducing probability of glass breakage in drug delivery devices
US11541168B2 (en) 2016-04-29 2023-01-03 Amgen Inc. Drug delivery device with messaging label
WO2017192287A1 (en) 2016-05-02 2017-11-09 Amgen Inc. Syringe adapter and guide for filling an on-body injector
EP3455142B1 (en) 2016-05-13 2023-08-09 Amgen Inc. Vial sleeve assembly
US11238150B2 (en) 2016-05-16 2022-02-01 Amgen Inc. Data encryption in medical devices with limited computational capability
HRP20220479T1 (hr) * 2016-06-01 2022-05-27 Athira Pharma, Inc. Spojevi
US11541176B2 (en) 2016-06-03 2023-01-03 Amgen Inc. Impact testing apparatuses and methods for drug delivery devices
WO2018004842A1 (en) 2016-07-01 2018-01-04 Amgen Inc. Drug delivery device having minimized risk of component fracture upon impact events
WO2018034784A1 (en) 2016-08-17 2018-02-22 Amgen Inc. Drug delivery device with placement detection
WO2018039557A1 (en) 2016-08-26 2018-03-01 Ngm Biopharmaceuticals, Inc. Methods of treating fibroblast growth factor 19-mediated cancers and tumors
US20200261643A1 (en) 2016-10-25 2020-08-20 Amgen Inc. On-body injector
WO2018094275A1 (en) 2016-11-18 2018-05-24 Tolero Pharmaceuticals, Inc. Alvocidib prodrugs and their use as protein kinase inhibitors
WO2018136398A1 (en) 2017-01-17 2018-07-26 Amgen Inc. Injection devices and related methods of use and assembly
US11752258B2 (en) 2017-02-17 2023-09-12 Amgen Inc. Drug delivery device with sterile fluid flowpath and related method of assembly
US11369736B2 (en) 2017-02-17 2022-06-28 Amgen Inc. Cannula insertion and retraction mechanisms
CA3050927A1 (en) 2017-03-06 2018-09-13 Brian Stonecipher Drug delivery device with activation prevention feature
KR102627069B1 (ko) 2017-03-07 2024-01-18 암겐 인코포레이티드 과압에 의한 바늘 삽입
EP3592404A1 (en) 2017-03-09 2020-01-15 Amgen Inc. Insertion mechanism for drug delivery device
KR102651078B1 (ko) 2017-03-28 2024-03-22 암겐 인코포레이티드 플런저 로드 및 주사기 조립 시스템 및 방법
BR112019019813A2 (pt) 2017-03-30 2020-04-22 The University Of Queensland moléculas quiméricas e usos das mesmas
JP7200134B2 (ja) 2017-06-08 2023-01-06 アムジエン・インコーポレーテツド トルク駆動式薬物送達デバイス
US11590294B2 (en) 2017-06-08 2023-02-28 Amgen Inc. Syringe assembly for a drug delivery device and method of assembly
JP7195276B2 (ja) 2017-06-22 2022-12-23 アムジエン・インコーポレーテツド デバイス起動による衝突／衝撃の低減
MA49461A (fr) 2017-06-23 2020-04-29 Amgen Inc Dispositif électronique d'administration de médicament comprenant un bouchon activé par un ensemble commutateur
MA49562A (fr) 2017-07-14 2020-05-20 Amgen Inc Système d'insertion-rétractation d'aiguille présentant un système à ressort en double torsion
EP3655063A1 (en) 2017-07-21 2020-05-27 Amgen Inc. Gas permeable sealing member for drug container and methods of assembly
US11484648B2 (en) 2017-07-25 2022-11-01 Amgen Inc. Drug delivery device with container access system and related method of assembly
MA49677A (fr) 2017-07-25 2021-04-21 Amgen Inc Dispositif d'administration de médicament avec module d'engrenage et procédé d'assemblage associé
MA49838A (fr) 2017-08-09 2020-06-17 Amgen Inc Systèm de administration de médicaments avec pression hydraulique-pneumatique de chambre
WO2019036181A1 (en) 2017-08-18 2019-02-21 Amgen Inc. BODY INJECTOR WITH STERILE ADHESIVE PATCH
US11103636B2 (en) 2017-08-22 2021-08-31 Amgen Inc. Needle insertion mechanism for drug delivery device
WO2019055579A1 (en) 2017-09-12 2019-03-21 Tolero Pharmaceuticals, Inc. TREATMENT REGIME FOR CANCERS THAT ARE INSENSITIVE TO BCL-2 INHIBITORS USING THE MCL-1 ALVOCIDIB INHIBITOR
WO2019070472A1 (en) 2017-10-04 2019-04-11 Amgen Inc. FLOW ADAPTER FOR MEDICATION DELIVERY DEVICE
CN111132711B (zh) 2017-10-06 2022-07-01 安进公司 带有联锁组件的药物递送装置及相关组装方法
MA50348A (fr) 2017-10-09 2020-08-19 Amgen Inc Dispositif d'administration de médicament comprenant un ensemble d'entraînement et procédé d'assemblage associé
WO2019090086A1 (en) 2017-11-03 2019-05-09 Amgen Inc. Systems and approaches for sterilizing a drug delivery device
US20200261648A1 (en) 2017-11-06 2020-08-20 Amgen Inc. Drug delivery device with placement and flow sensing
IL273664B1 (en) 2017-11-06 2026-02-01 Amgen Inc Full-fledged assemblies and related methods
IL319987A (en) 2017-11-10 2025-06-01 Amgen Inc Plungers for drug delivery devices
SG11202003004RA (en) 2017-11-16 2020-04-29 Amgen Inc Door latch mechanism for drug delivery device
AU2018368338B2 (en) 2017-11-16 2024-07-25 Amgen Inc. Autoinjector with stall and end point detection
US10835685B2 (en) 2018-05-30 2020-11-17 Amgen Inc. Thermal spring release mechanism for a drug delivery device
US11083840B2 (en) 2018-06-01 2021-08-10 Amgen Inc. Modular fluid path assemblies for drug delivery devices
CA3103681A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Delivery devices for administering drugs
WO2020023336A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Hybrid drug delivery devices with grip portion
WO2020023220A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Hybrid drug delivery devices with tacky skin attachment portion and related method of preparation
WO2020023451A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Delivery devices for administering drugs
EP3829692A1 (en) 2018-07-31 2021-06-09 Amgen Inc. Fluid path assembly for a drug delivery device
EP3856284A1 (en) 2018-09-24 2021-08-04 Amgen Inc. Interventional dosing systems and methods
MA53718A (fr) 2018-09-28 2022-01-05 Amgen Inc Ensemble d'activation d'échappement de fil de muscle pour un dispositif d'administration de médicament
MX2021003492A (es) 2018-10-02 2021-06-18 Amgen Inc Sistemas de inyeccion para la administracion de farmacos con transmision de fuerza interna.
JP7547325B2 (ja) 2018-10-05 2024-09-09 アムジエン・インコーポレーテツド 投薬量インジケータを有する薬物送達デバイス
AU2019359801B2 (en) 2018-10-15 2025-01-02 Amgen Inc. Platform assembly process for drug delivery device
SG11202103800RA (en) 2018-10-15 2021-05-28 Amgen Inc Drug delivery device having damping mechanism
TWI831847B (zh) 2018-11-01 2024-02-11 美商安進公司 部分針頭縮回之藥物遞送裝置及其操作方法
ES3010833T3 (en) 2018-11-01 2025-04-04 Amgen Inc Drug delivery devices with partial drug delivery member retraction
MA54057A (fr) 2018-11-01 2022-02-09 Amgen Inc Dispositifs d'administration de médicament à rétraction partielle d'élément d'administration de médicament
JP2022511029A (ja) 2018-12-04 2022-01-28 スミトモ ダイニッポン ファーマ オンコロジー， インコーポレイテッド がんの処置のための薬剤としての使用のためのｃｄｋ９インヒビターおよびその多形
JP2022525149A (ja) 2019-03-20 2022-05-11 スミトモ ダイニッポン ファーマ オンコロジー， インコーポレイテッド ベネトクラクスが失敗した急性骨髄性白血病（ａｍｌ）の処置
AU2020263289B2 (en) 2019-04-24 2025-05-22 Amgen Inc. Syringe sterilization verification assemblies and methods
CN114206942A (zh) 2019-06-07 2022-03-18 美国安进公司 双特异性结合构建体
EP3772518A1 (en) * 2019-08-07 2021-02-10 Merus N.V. Modified human variable domains
US20220275368A1 (en) 2019-08-12 2022-09-01 Interna Technologies B.V. New treatments involving mirna-193a
MX2022002149A (es) 2019-08-23 2022-03-17 Amgen Inc Dispositivo de suministro de farmacos con componentes de acoplamiento de capuchon de aguja configurable y metodos relacionados.
CN115461461A (zh) 2020-02-28 2022-12-09 因特尔纳技术有限公司 用于促进免疫原性细胞死亡的miRNA-193a
AU2021283933A1 (en) 2020-06-04 2023-01-05 Amgen Inc. Bispecific binding constructs
WO2022120033A1 (en) 2020-12-03 2022-06-09 Amgen Inc. Immunoglobuline constructs with multiple binding domains
WO2022192661A1 (en) * 2021-03-12 2022-09-15 Board Of Regents, The University Of Texas System Sars-cov-2 neutralizing antibodies and uses thereof
MX2023013640A (es) 2021-05-21 2023-11-30 Amgen Inc Metodo de optimizacion de una receta de llenado para un contenedor de medicamento.
TW202506733A (zh) 2023-06-12 2025-02-16 美商安進公司 淋巴毒素β受體促效劑結合蛋白
WO2026030152A1 (en) 2024-07-29 2026-02-05 Amgen Inc. System and method for assessing transferability of a fill recipe

Family Cites Families (140)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
US4615885A (en) 1983-11-01 1986-10-07 Terumo Kabushiki Kaisha Pharmaceutical composition containing urokinase
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
WO1988001649A1 (en) 1986-09-02 1988-03-10 Genex Corporation Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
JPS6427491A (en) 1987-07-14 1989-01-30 Yasushi Daikuhara Monoclonal antibody
US5520914A (en) * 1987-08-06 1996-05-28 President And Fellows Of Harvard College Antibodies to angiogenin: immunotherapeutic agents
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
JP3030312B2 (ja) * 1988-12-12 2000-04-10 敏一 中村 成熟肝実質細胞増殖因子（ｉ）
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5086164A (en) * 1989-01-10 1992-02-04 Repligen Corporation Novel methods and compositions for treatment of angiogenic diseases
JP2762522B2 (ja) 1989-03-06 1998-06-04 藤沢薬品工業株式会社 血管新生阻害剤
JPH02240100A (ja) * 1989-03-15 1990-09-25 Takara Shuzo Co Ltd 新規ポリペプチド
JP2877509B2 (ja) 1989-05-19 1999-03-31 アムジエン・インコーポレーテツド メタロプロテイナーゼ阻害剤
US5112946A (en) 1989-07-06 1992-05-12 Repligen Corporation Modified pf4 compositions and methods of use
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5871959A (en) * 1989-12-27 1999-02-16 The United States Of America As Represented By The Department Of Health And Human Services Method of producing hepatocycte growth factor/scatter factor and related cell lines
US5362716A (en) * 1989-12-27 1994-11-08 The United States Of America As Represented By The Department Of Health And Human Services Methods for stimulating hematopoietic progenitors using hepatocyte growth factor and lymphokines
GB9003621D0 (en) 1990-02-16 1990-04-11 Imp Cancer Res Tech Protein factor
US5151510A (en) 1990-04-20 1992-09-29 Applied Biosystems, Inc. Method of synethesizing sulfurized oligonucleotide analogs
GB9009548D0 (en) 1990-04-27 1990-06-20 Celltech Ltd Chimeric antibody and method
DE69133492T2 (de) 1990-06-11 2006-08-10 Nakamura, Toshikazu Rekombinanter menschlicher Hepatozytwachstumsfaktor und Verfahren zu seiner Herstellung
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5821223A (en) * 1990-09-14 1998-10-13 The United States Of America As Represented By The Department Of Health And Human Services Method of stimulating cell growth with a novel broad spectrum human lung fibroblast-derived mitogen
EP1069137A1 (en) 1990-09-24 2001-01-17 W.R. Grace & Co.-Conn. Peptides having thrombospondin-like activity and their therapeutic use
US5892112A (en) 1990-11-21 1999-04-06 Glycomed Incorporated Process for preparing synthetic matrix metalloprotease inhibitors
US5268384A (en) * 1990-11-21 1993-12-07 Galardy Richard E Inhibition of angiogenesis by synthetic matrix metalloprotease inhibitors
WO1992010210A1 (en) 1990-12-14 1992-06-25 E.I. Du Pont De Nemours And Company Inhibition of angiogenesis by il-1
ATE255131T1 (de) * 1991-06-14 2003-12-15 Genentech Inc Humanisierter heregulin antikörper
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
PT1696031E (pt) 1991-12-02 2010-06-25 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
JP4157160B2 (ja) 1991-12-13 2008-09-24 ゾーマ テクノロジー リミテッド 改変抗体可変領域の調製のための方法
US5869619A (en) 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
AU3328493A (en) 1991-12-17 1993-07-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
US5684136A (en) * 1992-05-18 1997-11-04 Genentech, Inc. Chimeric hepatocyte growth factor (HGF) ligand variants
CA2144856A1 (en) 1992-09-18 1994-03-31 Donna L. Faletto A method of preventing tumor metastasis
US6066718A (en) 1992-09-25 2000-05-23 Novartis Corporation Reshaped monoclonal antibodies against an immunoglobulin isotype
PT669929E (pt) 1992-11-13 2007-04-30 Immunex Corp Ligando de elk, uma citoquina
US5629327A (en) 1993-03-01 1997-05-13 Childrens Hospital Medical Center Corp. Methods and compositions for inhibition of angiogenesis
CA2158727A1 (en) * 1993-03-23 1994-09-29 Hiroshi Hara Parenchymal hepatocyte growth substances
US5516658A (en) 1993-08-20 1996-05-14 Immunex Corporation DNA encoding cytokines that bind the cell surface receptor hek
US6498144B1 (en) * 1993-10-18 2002-12-24 North Shore - Long Island Jewish Research Institute Use of scatter factor to enhance angiogenesis
US5837676A (en) * 1993-10-18 1998-11-17 Long Island Jewish Medical Center Use of scatter factor to enhance angiogenesis
US5700823A (en) 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers
US5429746A (en) * 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
AU702522B2 (en) 1994-04-15 1999-02-25 Amgen, Inc. HEK5, HEK7, HEK8, HEK11, new EPH-like receptor protein tyrosine kinases
US5707624A (en) * 1994-06-03 1998-01-13 The Regents Of The University Of Michigan Treatment of Kaposi's sarcoma by inhibition of scatter factor
US6303769B1 (en) 1994-07-08 2001-10-16 Immunex Corporation Lerk-5 dna
US5919905A (en) 1994-10-05 1999-07-06 Immunex Corporation Cytokine designated LERK-6
US5814464A (en) 1994-10-07 1998-09-29 Regeneron Pharma Nucleic acids encoding TIE-2 ligand-2
US6057124A (en) 1995-01-27 2000-05-02 Amgen Inc. Nucleic acids encoding ligands for HEK4 receptors
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
EP0822830B1 (en) 1995-04-27 2008-04-02 Amgen Fremont Inc. Human anti-IL-8 antibodies, derived from immunized xenomice
US5686292A (en) * 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
US6214344B1 (en) * 1995-06-02 2001-04-10 Genetech, Inc. Hepatocyte growth factor receptor antagonists and uses thereof
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
US6127977A (en) 1996-11-08 2000-10-03 Cohen; Nathan Microstrip patch antenna with fractal structure
DE19534177A1 (de) 1995-09-15 1997-03-20 Merck Patent Gmbh Cyclische Adhäsionsinhibitoren
US6090382A (en) * 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
US5783186A (en) 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis
US5827673A (en) * 1996-08-13 1998-10-27 Akira Matsumori Method of detecting myocardial infarction
WO1998019696A1 (en) 1996-11-05 1998-05-14 Smithkline Beecham Corporation Hepatocyte growth factor antagonists
ATE549918T1 (de) 1996-12-03 2012-04-15 Amgen Fremont Inc Menschliche antikörper, die ausdrücklich menschliches tnf alpha binden
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
US6133426A (en) 1997-02-21 2000-10-17 Genentech, Inc. Humanized anti-IL-8 monoclonal antibodies
US20020032315A1 (en) * 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
CA2205096C (en) * 1997-05-09 2001-10-09 Ibm Canada Limited-Ibm Canada Limitee A system for remote debugging of client/server applications
US6171586B1 (en) * 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US6232456B1 (en) * 1997-10-06 2001-05-15 Abbott Laboratories Serine protease reagents and methods useful for detecting and treating diseases of the prostate
RS49779B (sr) 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
ES2324846T3 (es) 1998-03-04 2009-08-17 Bristol-Myers Squibb Company Inhibidores de la proteina tirosina quinasa de imidazopirazina heterociclo-sustituida.
WO1999046291A1 (en) 1998-03-12 1999-09-16 Shanghai Second Medical University A human glia maturation factor (gmf) beta homolog gene (cbfboe11)
AU3202999A (en) 1998-03-26 1999-10-18 Long Island Jewish Medical Center Use of scatter factor to enhance angiogenesis
BRPI9910332B8 (pt) * 1998-05-06 2021-05-25 Genentech Inc método para purificação de um polipeptídio a partir de uma composição
IL139934A0 (en) 1998-05-29 2002-02-10 Sugen Inc Pyrrole substituted 2-indolinone derivatives and pharmaceutical compositions containing the same
UA60365C2 (uk) 1998-06-04 2003-10-15 Пфайзер Продактс Інк. Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця
CA2336848A1 (en) 1998-07-10 2000-01-20 Merck & Co., Inc. Novel angiogenesis inhibitors
WO2000012560A1 (en) * 1998-08-28 2000-03-09 Dendreon Corporation Selective apoptosis of neoplastic cells by an hla-dr specific monoclonal antibody
EP1109555A4 (en) 1998-08-31 2001-11-21 Merck & Co Inc Novel angiogenesis inhibitors
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
CA2359244C (en) 1999-01-13 2013-10-08 Bayer Healthcare Llc .omega.-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
JP4673977B2 (ja) 1999-03-30 2011-04-20 ノバルティス アーゲー 炎症性疾患治療用フタラジン誘導体
ATE324444T1 (de) 1999-06-07 2006-05-15 Immunex Corp Tek-antagonisten
US6521424B2 (en) 1999-06-07 2003-02-18 Immunex Corporation Recombinant expression of Tek antagonists
CN100376567C (zh) 1999-11-05 2008-03-26 阿斯特拉曾尼卡有限公司 作为vegf抑制剂的喹唑啉衍生物
AU1598801A (en) * 1999-11-09 2001-06-06 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The HGF-SF monoclonal antibody combinations
DK1233943T3 (da) 1999-11-24 2011-08-15 Sugen Inc Ioniserbare indolinon derivater og anvendelse deraf som PTK ligander
US6515004B1 (en) 1999-12-15 2003-02-04 Bristol-Myers Squibb Company N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases
US6727225B2 (en) 1999-12-20 2004-04-27 Immunex Corporation TWEAK receptor
DK1255829T3 (da) 2000-02-11 2009-12-14 Genentech Inc Inhibitor af hepatocytvækstfaktoraktivator til anvendelse i modulation af angiogenese og kardiovaskularisering
EP1259595B1 (en) 2000-02-25 2007-04-04 Immunex Corporation Integrin antagonists
EP1274731A1 (en) 2000-03-13 2003-01-15 Eli Lilly And Company Human hepatocyte growth factor activator inhibitor homologue
GB0006398D0 (en) * 2000-03-16 2000-05-03 Novartis Ag Organic compounds
US6749847B2 (en) * 2000-03-30 2004-06-15 The University Of Connecticut Hybrid cytokine of IL-7 and β-chain of hepatocyte growth factor
AU5943201A (en) 2000-05-03 2001-11-12 Amgen Inc Modified peptides as therapeutic agents
JP3597140B2 (ja) * 2000-05-18 2004-12-02 日本たばこ産業株式会社 副刺激伝達分子ａｉｌｉｍに対するヒトモノクローナル抗体及びその医薬用途
AU7785401A (en) 2000-06-29 2002-01-14 Long Island Jewish Res Inst Modulators of cellular proliferation and angiogenesis, methods for use and identification thereof
US6902734B2 (en) * 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
US6630500B2 (en) 2000-08-25 2003-10-07 Cephalon, Inc. Selected fused pyrrolocarbazoles
ES2556946T3 (es) 2000-12-21 2016-01-21 Novartis Ag Pirimidinaminas como moduladores de la angiogénesis
US6995162B2 (en) 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
US7105682B2 (en) 2001-01-12 2006-09-12 Amgen Inc. Substituted amine derivatives and methods of use
US6878714B2 (en) 2001-01-12 2005-04-12 Amgen Inc. Substituted alkylamine derivatives and methods of use
US20020147198A1 (en) 2001-01-12 2002-10-10 Guoqing Chen Substituted arylamine derivatives and methods of use
US7102009B2 (en) 2001-01-12 2006-09-05 Amgen Inc. Substituted amine derivatives and methods of use
US7138370B2 (en) 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
US7205275B2 (en) 2001-10-11 2007-04-17 Amgen Inc. Methods of treatment using specific binding agents of human angiopoietin-2
US7521053B2 (en) 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
EP1516185A4 (en) 2001-12-27 2007-06-20 Van Andel Res Inst Monoclonal antibody imaging and therapy of tumors that express met and bind hepatocyte growth factor
CN1376923A (zh) * 2002-04-08 2002-10-30 刘友华 肝细胞生长因子的测定方法
US7307088B2 (en) 2002-07-09 2007-12-11 Amgen Inc. Substituted anthranilic amide derivatives and methods of use
TWI329112B (en) 2002-07-19 2010-08-21 Bristol Myers Squibb Co Novel inhibitors of kinases
US7220410B2 (en) * 2003-04-18 2007-05-22 Galaxy Biotech, Llc Monoclonal antibodies to hepatocyte growth factor
US20040208876A1 (en) 2003-04-18 2004-10-21 Kim Kyung Jin Monoclonal antibodies to hepatocyte growth factor
EP2093570A1 (en) 2003-06-06 2009-08-26 Genentech, Inc. Modulating the interaction between HGF beta chain and c-met
NZ544797A (en) * 2003-07-18 2011-04-29 Amgen Fremont Inc Specific antibodies that bind HGF and neutralise binding of HGF to met
AR059922A1 (es) 2006-04-01 2008-05-07 Galaxy Biotech Llc Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos
SG158112A1 (en) 2006-06-02 2010-01-29 Aveo Pharmaceuticals Inc Hepatocyte growth factor (hgf) binding proteins
US9300829B2 (en) 2014-04-04 2016-03-29 Canon Kabushiki Kaisha Image reading apparatus and correction method thereof

Also Published As

Publication number Publication date
ZA200601353B (en) 2008-11-26
RS53476B (sr) 2014-12-31
JP2012235783A (ja) 2012-12-06
CN103880955A (zh) 2014-06-25
BRPI0412885A (pt) 2006-10-03
US8609090B2 (en) 2013-12-17
CA2532027C (en) 2016-06-14
AR042955A1 (es) 2005-07-13
NO20060600L (no) 2006-04-18
PT1648998E (pt) 2014-11-04
JP2007530003A (ja) 2007-11-01
CN101124240B (zh) 2013-12-18
NZ544797A (en) 2011-04-29
PL1648998T3 (pl) 2015-03-31
JP5105874B2 (ja) 2012-12-26
JP5543315B2 (ja) 2014-07-09
RS20050975A (sr) 2008-06-05
IL172906A0 (en) 2006-06-11
EA015363B1 (ru) 2011-06-30
AU2004265595B2 (en) 2011-12-08
TW200524958A (en) 2005-08-01
US20050118643A1 (en) 2005-06-02
EP1648998A2 (en) 2006-04-26
AR086511A2 (es) 2013-12-18
KR20060054321A (ko) 2006-05-22
SI1648998T1 (sl) 2015-01-30
EP1648998B1 (en) 2014-10-01
TW201319087A (zh) 2013-05-16
EP1648998A4 (en) 2007-11-14
WO2005017107A2 (en) 2005-02-24
US20140154243A1 (en) 2014-06-05
HK1087437A1 (en) 2006-10-13
TW201319088A (zh) 2013-05-16
KR101254371B1 (ko) 2013-05-02
JP5750021B2 (ja) 2015-07-15
HK1199266A1 (en) 2015-06-26
CN101124240A (zh) 2008-02-13
TWI395756B (zh) 2013-05-11
KR20110129988A (ko) 2011-12-02
WO2005017107A3 (en) 2007-03-01
MXPA06000508A (es) 2006-04-05
CA2532027A1 (en) 2005-02-24
JP2012051901A (ja) 2012-03-15
JP2011079837A (ja) 2011-04-21
EA200600233A1 (ru) 2007-04-27
ZA200803050B (en) 2010-08-25
SG131943A1 (en) 2007-05-28
DK1648998T3 (en) 2015-01-05
TWI476206B (zh) 2015-03-11
AU2004265595A1 (en) 2005-02-24
MEP31408A (en) 2010-10-10
CN103755807A (zh) 2014-04-30
EP2341067A1 (en) 2011-07-06
AR086510A2 (es) 2013-12-18

Similar Documents

Publication Publication Date Title
ES2525477T3 (es) Anticuerpos anti-factor D humanizados
ES2512141T3 (es) Análogo peptídico de oxintomodulina
ES2486675T3 (es) Análogo de péptido de oxintomodulina
ES2535084T3 (es) Proteínas N-glicosiladas recombinantes procedentes de células procariotas
DK2316852T3 (da) Stabiliserede enkeltdomæne-antistoffer
IL195338A (en) An antibody comprising an FC variant containing amino acid replaces d or e at position 239, a medicament containing it and its use
ATE401390T1 (de) Zytokin (zcytor17-ligand)
EP1731605A4 (en) CANCERANT PEPTIDES FROM WT1
CY1118443T1 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοι και χρησεις
ATE368688T1 (de) Peptide, deren herstellung und verwendung zur bindung von immunglobulinen
ATE404225T1 (de) Radiofluorierte peptide
EP2360180A3 (en) Pancreatic polypeptide family motifs, polypeptides and methods comprising the same
DE60234085D1 (de) Rekombinantes super-verbindungs-interferon zur verwendung als hepatitis b oberflächenatigen und e-antigen-inhibitor
EA200700973A1 (ru) Слитый белок, содержащий домен bh3 белка «вh3-только»
ES2487637T3 (es) Moduladores de PDZ Disheveled
DE60335726D1 (de) Chromoprotein und fluoroproteine
ATE491349T1 (de) Neue nutrazeutika-zusammensetzungen
EA200801174A1 (ru) Антитела-миметики glp-2, полипептиды, композиции, способы и применения
ATE447612T1 (de) Fluoreszenzproteine
ATE529445T1 (de) Biokinetik zur schnellen beseitigung von polypeptiden
ES2507094T3 (es) Proteína específica del timo
ES2557938T3 (es) Antagonistas de resistina y su uso
IS8308A (is) Amínósýrur með sækni fyrir a2o prótíninu
CR8167A (es) Procedimiento para la preparacion de derivados de espirobenzoacepina sustituida no peptidica
ATE550345T1 (de) Sfrp, mit sfrp-interagierende peptidmotive sowie verwendungsverfahren